Literature DB >> 26898758

Epigenetic modulation of a miR-296-5p:HMGA1 axis regulates Sox2 expression and glioblastoma stem cells.

H Lopez-Bertoni1,2, B Lal1,2, N Michelson1, H Guerrero-Cázares3, A Quiñones-Hinojosa3,4,5, Y Li1,2, J Laterra1,2,4,5.   

Abstract

Solid malignancies contain subsets of multipotent cells that grow as spheres and efficiently propagate tumors in xenograft models, reflecting a stem-like, self-renewing and tumor-propagating phenotype. These cancer 'stem cells (SCs)' have been shown to maintain tumor growth, contribute to resistance and drive tumor recurrence. Cancer cell stemness is dynamically influenced by epigenetic mechanisms and differentially regulated coding and noncoding RNAs. How these mechanisms specifically contribute to the generation and/or maintenance of cancer SCs remains unclear. This study identifies a novel epigenetically regulated circuit that integrates microRNA, chromatin remodeling and the reprogramming transcription factor Sox2 to regulate glioblastoma (GBM)-propagating SCs. We show that miR-296-5p expression is repressed in a DNA methylation-dependent manner under conditions that promote GBM cell stemness and that miR-296-5p inhibits GBM cell stemness and their capacity to self-renew as spheres and propagate glioma xenografts in vivo. We show that the chromatin remodeling protein HMGA1 functions as a downstream effector of these biological responses to miR-296-5p and regulates Sox2 expression, a master driver of cell stemness, by modifying chromatin architecture at the Sox2 promoter. These results show for the first time that miR-296-5p inhibits transcriptional mechanisms that support GBM SCs and identify a miR-296-5p:HMGA1:Sox2 axis as a novel regulator of GBM SCs and candidate pathway for targeting therapies directed at depleting tumors of their tumor-propagating stem cell subsets.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 26898758      PMCID: PMC6151872          DOI: 10.1038/onc.2016.22

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  46 in total

1.  PROMO: detection of known transcription regulatory elements using species-tailored searches.

Authors:  Xavier Messeguer; Ruth Escudero; Domènec Farré; Oscar Núñez; Javier Martínez; M Mar Albà
Journal:  Bioinformatics       Date:  2002-02       Impact factor: 6.937

2.  The prognostic and chemotherapeutic value of miR-296 in esophageal squamous cell carcinoma.

Authors:  Liu Hong; Yu Han; Hongwei Zhang; Mengbin Li; Taiqian Gong; Li Sun; Kaichun Wu; Qingchuan Zhao; Daiming Fan
Journal:  Ann Surg       Date:  2010-06       Impact factor: 12.969

3.  MicroRNAs 296 and 298 are imprinted and part of the GNAS/Gnas cluster and miR-296 targets IKBKE and Tmed9.

Authors:  Joan E Robson; Sally A Eaton; Peter Underhill; Debbie Williams; Jo Peters
Journal:  RNA       Date:  2011-11-23       Impact factor: 4.942

4.  Regulation of HMGA1 expression by microRNA-296 affects prostate cancer growth and invasion.

Authors:  Jian-Jun Wei; Xinyu Wu; Yi Peng; Guizhi Shi; Olca Basturk; Basturk Olca; Ximing Yang; Garrett Daniels; Iman Osman; Jiangyong Ouyang; Eva Hernando; Angel Pellicer; Johng S Rhim; Jonathan Melamed; Peng Lee
Journal:  Clin Cancer Res       Date:  2010-12-07       Impact factor: 12.531

Review 5.  Cancer stem cells: an evolving concept.

Authors:  Long V Nguyen; Robert Vanner; Peter Dirks; Connie J Eaves
Journal:  Nat Rev Cancer       Date:  2012-01-12       Impact factor: 60.716

6.  Highly efficient miRNA-mediated reprogramming of mouse and human somatic cells to pluripotency.

Authors:  Frederick Anokye-Danso; Chinmay M Trivedi; Denise Juhr; Mudit Gupta; Zheng Cui; Ying Tian; Yuzhen Zhang; Wenli Yang; Peter J Gruber; Jonathan A Epstein; Edward E Morrisey
Journal:  Cell Stem Cell       Date:  2011-04-08       Impact factor: 24.633

7.  The scatter factor/hepatocyte growth factor: c-met pathway in human embryonal central nervous system tumor malignancy.

Authors:  Yunqing Li; Bachchu Lal; Sherwin Kwon; Xing Fan; Usha Saldanha; Thomas E Reznik; Eric B Kuchner; Charles Eberhart; John Laterra; Roger Abounader
Journal:  Cancer Res       Date:  2005-10-15       Impact factor: 12.701

8.  Hierarchical maintenance of MLL myeloid leukemia stem cells employs a transcriptional program shared with embryonic rather than adult stem cells.

Authors:  Tim C P Somervaille; Christina J Matheny; Gary J Spencer; Masayuki Iwasaki; John L Rinn; Daniela M Witten; Howard Y Chang; Sheila A Shurtleff; James R Downing; Michael L Cleary
Journal:  Cell Stem Cell       Date:  2009-02-06       Impact factor: 24.633

9.  Contrasting in vivo and in vitro fates of glioblastoma cell subpopulations with amplified EGFR.

Authors:  Ajay Pandita; Kenneth D Aldape; Gelareh Zadeh; Abhijit Guha; C David James
Journal:  Genes Chromosomes Cancer       Date:  2004-01       Impact factor: 5.006

10.  Regulation of somatic cell reprogramming through inducible mir-302 expression.

Authors:  Shi-Lung Lin; Donald C Chang; Chun-Hung Lin; Shao-Yao Ying; Davey Leu; David T S Wu
Journal:  Nucleic Acids Res       Date:  2010-09-24       Impact factor: 16.971

View more
  25 in total

Review 1.  Mutual regulation of microRNAs and DNA methylation in human cancers.

Authors:  Sumei Wang; Wanyin Wu; Francois X Claret
Journal:  Epigenetics       Date:  2017-01-06       Impact factor: 4.528

2.  SOX2 Inhibition Promotes Promoter Demethylation of CDX2 to Facilitate Gastric Intestinal Metaplasia.

Authors:  Haijing Niu; Yuchen Jia; Tao Li; Bingzhong Su
Journal:  Dig Dis Sci       Date:  2016-12-02       Impact factor: 3.199

Review 3.  High Mobility Group A1 (HMGA1): Structure, Biological Function, and Therapeutic Potential.

Authors:  Lu Wang; Ji Zhang; Min Xia; Chang Liu; Xuyu Zu; Jing Zhong
Journal:  Int J Biol Sci       Date:  2022-07-04       Impact factor: 10.750

4.  MicroRNA-296-5p inhibits cell proliferation by targeting HMGA1 in colorectal cancer.

Authors:  Guohui Yan; Shuidi Yan; Jiajia Wang; Shen Lei; Weimin Tian; Xin Yue; Yang Zhang
Journal:  Exp Ther Med       Date:  2021-05-24       Impact factor: 2.447

5.  miR-484/MAP2/c-Myc-positive regulatory loop in glioma promotes tumor-initiating properties through ERK1/2 signaling.

Authors:  Renhui Yi; Jiugeng Feng; Shaochun Yang; Xiaoyu Huang; Yuanyuan Liao; Zheng Hu; Muyun Luo
Journal:  J Mol Histol       Date:  2018-02-26       Impact factor: 2.611

6.  ShRNA-based POLD2 expression knockdown sensitizes glioblastoma to DNA-Damaging therapeutics.

Authors:  Qingfu Xu; Chengchen Hu; Yan Zhu; Kimberly Wang; Bachuchu Lal; Lichao Li; Junhai Tang; Shuang Wei; Guohao Huang; Shuli Xia; Shengqing Lv; John Laterra; Yugang Jiang; Yunqing Li
Journal:  Cancer Lett       Date:  2020-01-16       Impact factor: 8.679

Review 7.  Innovations in Biomaterial Design toward Successful RNA Interference Therapy for Cancer Treatment.

Authors:  Deidra M Ward; Aaliyah B Shodeinde; Nicholas A Peppas
Journal:  Adv Healthc Mater       Date:  2021-05-11       Impact factor: 11.092

8.  Reprogramming Transcription Factors Oct4 and Sox2 Induce a BRD-Dependent Immunosuppressive Transcriptome in GBM-Propagating Cells.

Authors:  Tengjiao Ma; Chengchen Hu; Bachchu Lal; Weiqiang Zhou; Yongxin Ma; Mingyao Ying; Panagiotis Prinos; Alfredo Quiñones-Hinojosa; Michael Lim; John Laterra; Yunqing Li
Journal:  Cancer Res       Date:  2021-02-11       Impact factor: 13.312

Review 9.  Regulation of DNA methylation machinery by epi-miRNAs in human cancer: emerging new targets in cancer therapy.

Authors:  Mohammad Reza Karimzadeh; Peyman Pourdavoud; Naeim Ehtesham; Mohaddese Qadbeigi; Masood Movahedi Asl; Behrang Alani; Meysam Mosallaei; Bahram Pakzad
Journal:  Cancer Gene Ther       Date:  2020-08-10       Impact factor: 5.987

10.  A Sox2:miR-486-5p Axis Regulates Survival of GBM Cells by Inhibiting Tumor Suppressor Networks.

Authors:  Hernando Lopez-Bertoni; Ivan S Kotchetkov; Nicole Mihelson; Bachchu Lal; Yuan Rui; Heather Ames; Maria Lugo-Fagundo; Hugo Guerrero-Cazares; Alfredo Quiñones-Hinojosa; Jordan J Green; John Laterra
Journal:  Cancer Res       Date:  2020-02-24       Impact factor: 12.701

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.